Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02601625 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02601625 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 30 participants.
The verdict
NCT02601625, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase I, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Pharmacokinetics and Safety of anifrolumab following Single-Dose administration to healthy subjects
Interventions
- DRUG Anifrolumab SC injection (300mg)
- DRUG Anifrolumab IV infusion (300mg)
- DRUG Anifrolumab SC infusion (600mg)
- DRUG Anifrolumab placebo SC injection (300mg)
- DRUG Anifrolumab placebo IV infusion (300mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-11-16 |
| Est. Completion | 2016-05-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02601625
The ClinicalTrials.gov registry entry for NCT02601625 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Anifrolumab SC injection (300mg) is the first listed.
NCT02601625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02601625 about?
NCT02601625 is a clinical study titled "A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects". This is a Phase I, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Pharmacokinetics and Safety of anifrolumab following Single-Dose administration to healthy subjects
What is the current status of trial NCT02601625?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2015-11-16. Estimated completion is 2016-05-25.
What interventions are being tested in trial NCT02601625?
The interventions under investigation include: Anifrolumab SC injection (300mg) (DRUG), Anifrolumab IV infusion (300mg) (DRUG), Anifrolumab SC infusion (600mg) (DRUG), Anifrolumab placebo SC injection (300mg) (DRUG), Anifrolumab placebo IV infusion (300mg) (DRUG).
Who is sponsoring clinical trial NCT02601625?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.